The rate of TROP2 positivity was markedly lower than for EpCAM in testicular germ cell tumors, neuroendocrine neoplasms, renal cell tumors, and also in many gastrointestinal adenocarcinomas. Here, TACSTD2 is linked to neuroendocrine neoplasm.